AOD 9604 half-life is often cited at roughly 20 to 30 minutes, which shapes how often it's injected. Learn what the research says and what to consider.
AOD 9604 has a reported half-life of roughly 20 to 30 minutes after subcutaneous injection, making it one of the shortest-acting peptides studied for fat loss. That narrow window is the main reason research protocols usually call for once-daily or split daily dosing rather than a single weekly shot. AOD 9604 is a synthetic fragment of human growth hormone (amino acids 176–191) and is not FDA-approved for human use in the United States.
What Is AOD 9604?
AOD 9604, also written AOD9604 or AOD-9604, is a 16-amino-acid piece of the growth hormone molecule. Researchers designed it to target fat metabolism without triggering the blood sugar swings and IGF-1 spikes linked to full-length HGH.
Because it is a research chemical, most information about it comes from small human trials run in the 1990s and 2000s, plus animal and lab studies. The FDA has not approved it for weight loss, and it is not a lawful ingredient in dietary supplements.
- Class: Synthetic peptide fragment of HGH (hGH 176–191)
- Common research dose: 250–500 mcg per day in older studies
- Route: Subcutaneous injection in most protocols
- Regulatory status: Not approved for human use in the US
How Long AOD 9604 Stays Active in the Body
Pharmacokinetic data on AOD 9604 in humans are limited, and most figures come from early sponsor studies rather than large independent trials. The generally cited half-life is about 20 to 30 minutes.
A short half-life means the peptide clears quickly from the bloodstream. Using standard pharmacology math, most of a dose would be gone within roughly two hours, though that is a rough guide rather than a precise number.
That does not mean the metabolic effects stop the moment blood levels drop. Downstream changes in fat breakdown can outlast the peptide itself, which is one reason daily dosing is used.
Why the Short Half-Life Shapes Dosing Schedules
Because AOD 9604 clears quickly, a weekly injection would leave long gaps with little active peptide available. Most research and community protocols therefore use daily administration, often in the morning or before activity.
If you are researching an aod 9604 dosage, you will typically see 250 mcg to 500 mcg per day cited. Some users split that into two smaller injections to spread exposure across the day, though there is no strong clinical evidence that splitting improves results.
Keep expectations realistic: the older human trials showed modest average fat loss, not dramatic transformation, and results varied widely between participants.
AOD 9604 Compared With Tesamorelin and MOTS-c
Half-life is one of the clearest differences between AOD 9604 and other peptides marketed for body composition. The table below summarizes commonly cited figures.
| Peptide | Approx. half-life | FDA status | Typical dosing |
|---|---|---|---|
| AOD 9604 | ~20–30 minutes | Not approved | Daily, 250–500 mcg |
| Tesamorelin | ~26–38 minutes | Approved for HIV-related lipodystrophy | Daily, 2 mg |
| MOTS-c | Not well characterized in humans | Not approved | Research use only |
An aod 9604 vs tesamorelin comparison usually comes down to three things: tesamorelin holds an FDA approval for a specific condition, has a much larger clinical dataset, and costs far more. AOD 9604 is cheaper and easier to source, but its evidence base is thinner.
An aod 9604 vs mots-c comparison is harder to make because MOTS-c is a mitochondrial-derived peptide with very limited human pharmacokinetic data. Most of what is known about MOTS-c comes from cell and animal research.
What Can Change How Long It Lasts
Half-life is not the only factor that determines how much peptide is available after a dose. Several practical variables matter.
Reconstitution and handling
Proper aod 9604 reconstitution with bacteriostatic water, the correct concentration, and cold storage all affect stability. A peptide that has degraded in the vial may appear to have a shorter effective duration simply because less intact peptide was injected.
Injection site and absorption
Subcutaneous injections are absorbed at different rates depending on the site and local blood flow. Abdominal injections tend to absorb faster than thigh injections, which slightly changes the time to peak concentration.
Individual metabolism
Body weight, kidney and liver function, age, and activity level can all shift how quickly any peptide is cleared. Two people using the same dose may see different blood-level curves.
Combination use
Some people ask about stacking AOD 9604 alongside prescription GLP-1 drugs such as tirzepatide, but no clinical trial has tested that combination. Mixing a research peptide with a prescription medication raises unknown risks and should be discussed with a physician.
Safety, Side Effects, and Legal Status
Reported side effects in the older AOD 9604 trials were generally mild and included headache, injection-site irritation, and brief nausea. Any honest aod 9604 benefits and side effects review should also note that long-term safety data are essentially absent.
AOD 9604 is not FDA-approved, and the FDA has warned that it is not a legal dietary supplement ingredient. Products sold online may be mislabeled, underdosed, or contaminated. Anyone considering it should talk with a licensed healthcare professional first, especially people with diabetes, those who are pregnant, or anyone taking other medications.
Bottom Line
AOD 9604's short half-life of roughly 20 to 30 minutes is the defining feature of its pharmacology. That brief window explains daily dosing, limits how much can accumulate from a single injection, and separates it from longer-acting peptides like tesamorelin.
The evidence base remains small, the product is not approved for human use, and online reviews vary widely in quality. Treat half-life data as one piece of the puzzle, not proof of effectiveness.
Frequently Asked Questions
How long does AOD 9604 stay in your system?
AOD 9604 is generally reported to have a half-life of about 20 to 30 minutes after subcutaneous injection. Using standard clearance estimates, most of a single dose would be gone within roughly two hours. These figures come from limited early studies, so individual results can vary.
Does a short half-life mean AOD 9604 doesn't work?
Not necessarily. A short half-life means the peptide clears from the blood quickly, but the metabolic effects it triggers can last longer than the drug itself. That said, human trials of AOD 9604 showed only modest average fat loss, and the peptide is not FDA-approved for human use.
How often is AOD 9604 injected?
Most research and community protocols use once-daily subcutaneous injections, typically 250 to 500 mcg. Some users split the dose into two smaller injections, but there is no clinical evidence that this improves outcomes. Because the product is unapproved and unregulated, anyone considering it should speak with a healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.